<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419041</url>
  </required_header>
  <id_info>
    <org_study_id>A8081020</org_study_id>
    <nct_id>NCT01419041</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function</brief_title>
  <official_title>A Phase I, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is being conducted to evaluate whether or not severe renal impairment has&#xD;
      an effect on crizotinib Pharmacokinetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma AUCinf (Area under the plasma concentration versus time curve from zero to infinity) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Cmax (Maximum plasma concentration) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma AUClast (Area under the plasma concentration versus time curve from zero to the last quantifiable concentration) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Time to Cmax) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (Apparent oral clearance) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (Apparent volume of distribution after oral dose) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fu (fraction of unbound drug in plasma) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,u (unbound AUCinf) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast,u (unbound AUClast) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,u (unbound Cmax) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/Fu (unbound apparent oral clearance) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR (Renal clearance) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae (Cumulative amount of drug recovered unchanged in the urine) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae% (Cumulative amount of drug recovered unchanged in the urine expressed as fraction of administered dose) for crizotinib</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf (Area under the plasma concentration versus time curve from zero to infinity) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast (Area under the plasma concentration versus time curve from zero to the last quantifiable concentration) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum plasma concentration) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Time to Cmax) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fu (fraction of unbound drug in plasma) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,u (unbound AUCinf) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast,u (unbound AUClast) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,u (unbound Cmax) for PF-06260182</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CLCR: Creatinine clearance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CLCR: Creatinine clearance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =&gt;90 mL/min)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr &lt;30 mL/min)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          -  Healthy male and/or female of non childbearing potential subjects between the ages of&#xD;
             18 and 65 years, inclusive ('healthy' is defined as no clinically relevant&#xD;
             abnormalities identified by a detailed medical history, full physical examination,&#xD;
             including blood pressure and pulse rate measurement, 12 lead ECG, and clinical&#xD;
             laboratory tests).&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 40 kg/m2 inclusive; and a total body weight &gt;50 kg&#xD;
             (&gt;110 lbs).&#xD;
&#xD;
        Subjects with Normal Renal Function (Group 1)&#xD;
&#xD;
          -  Normal renal function (CLcr =&gt;90 mL/min) during the screening period.&#xD;
&#xD;
          -  Matched 1-to-1 to subjects in Group 2 with respect to age (+/-5 years), weight (+/-10&#xD;
             kg), gender, and race according to protocol.&#xD;
&#xD;
        Subjects with Severe Renal Impairment (Groups 2)&#xD;
&#xD;
          -  Good general health commensurate with the population with chronic kidney disease.&#xD;
&#xD;
          -  Severe renal impairment (CLcr&lt;30 mL/min) during the screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          -  Renal allograft recipients.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption.&#xD;
&#xD;
          -  12 lead ECG demonstrating QTc &gt;470 msec at screening.&#xD;
&#xD;
          -  Urinary incontinence without catheterization.&#xD;
&#xD;
          -  A positive urine drug screen.&#xD;
&#xD;
          -  History of regular alcohol consumption.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days (or as determined by the local&#xD;
             requirement, whichever is longer) or 5 half lives preceding the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Pregnant or nursing females; females of childbearing potential, including those with&#xD;
             tubal ligation.&#xD;
&#xD;
          -  Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.&#xD;
&#xD;
        Subjects with Severe Renal Impairment (Groups 2)&#xD;
&#xD;
          -  Subjects with any significant hepatic, cardiac or pulmonary disease (apart from stable&#xD;
             ischemic heart disease), or subjects who are clinically nephrotic.&#xD;
&#xD;
          -  Subjects requiring hemodialysis.&#xD;
&#xD;
          -  Subjects with strict fluid restriction (ie, &lt;1500 mL/24 hours).&#xD;
&#xD;
          -  Significant bleeding diathesis which could preclude multiple venipuncture.&#xD;
&#xD;
          -  Use of food or drugs that are CYP3A4 inhibitors and inducers.&#xD;
&#xD;
          -  Herbal supplements and hormone replacement therapy must be discontinued 28 days prior&#xD;
             to the first dose of trial medication&#xD;
&#xD;
          -  Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081020&amp;StudyName=A%20Study%20to%20Evaluate%20The%20Pharmacokinetics%20Of%20Crizotinib%20%28PF-02341066%29%20In%20Subjects%20With%20Impaired%20Renal%20Function%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal impairment</keyword>
  <keyword>crizotinib</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

